Comparative Pharmacology
Head-to-head clinical analysis: BEYAZ versus DASETTA 1 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BEYAZ versus DASETTA 1 35.
BEYAZ vs DASETTA 1/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and drospirenone suppresses gonadotropins (FSH and LH) from the pituitary, inhibiting ovulation, altering cervical mucus, and inducing endometrial changes. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity.
Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone). Suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus (impenetrability to sperm) and endometrium (reduced likelihood of implantation).
One tablet (drospirenone 3 mg / ethinyl estradiol 0.02 mg) orally once daily for 24 days, followed by 4 days of placebo.
One tablet orally once daily, each containing 1 mg norethindrone acetate and 35 mcg ethinyl estradiol.
None Documented
None Documented
Drospirenone: approximately 30 hours (terminal). Ethinyl estradiol: approximately 13-15 hours (terminal). Steady-state reached within 10 days. Clinical context: once-daily dosing maintains therapeutic levels with minimal accumulation after 3-4 cycles.
Norethindrone: 5-14 hours (mean 8 hours); ethinyl estradiol: 10-20 hours (mean 14 hours). Clinical context: steady-state achieved within 5-7 days.
Urine (45-55% as metabolites), feces (30-40% as metabolites), with enterohepatic recirculation of ethinyl estradiol metabolites.
Renal (55-60% as metabolites, 25-30% as unchanged drug and conjugates), biliary/fecal (30-35% as metabolites).
Category C
Category C
Oral Contraceptive
Oral Contraceptive